We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · November 18, 2020

Efficacy and Safety of Tafamidis Doses in Transthyretin Cardiomyopathy

European Journal of Heart Failure


Additional Info

European Journal of Heart Failure
Efficacy and Safety of Tafamidis Doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and Long-Term Extension Study
Eur. J. Heart Fail 2020 Oct 18;[EPub Ahead of Print], T Damy, P Garcia-Pavia, M Hanna, DP Judge, G Merlini, B Gundapaneni, TA Patterson, S Riley, JH Schwartz, MB Sultan, R Witteles

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading